Roche’s move to skip over Inovio’s (NYSE: INO) late stage drugs for cervical cancer and Hepatitis C and make a beeline for its preclinical DNA vaccines for prostate cancer and Hep B was initially a little puzzling. Investors have preferred to park their money further upstream when products are in the clinic and they’ve been derisked. Big pharma is always looking for ways to take costs out of research and development. But the prospect of utilizing new technology with the potential to improve treatment is appealing for drug developers that want to build up and strengthen their drug pipeline.
{iframe}http://medcitynews.com/2013/09/whats-attracting-big-pharma-to-pre-clinical-deals/{/iframe}